Drugs / OXELUMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01152619 | Jul 2010 → Feb 2011 | asthma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00983658 | Sep 2009 → Aug 2010 | asthma | Genentech, Inc. | Completed | Missed primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OXELUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108720 ↗ |
| Known as | huMAb OX40L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00983658 ↗ |
| Known as | R-4930 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108720 ↗ |
| Known as | R-4930 HUMAB OX40L | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108720 ↗ |
| Known as | RO4989991 | “Intravenous huMAb OX40L (RO4989991) in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma” NCT00983658 ↗ |
| Action | Inhibit | “Tumor necrosis factor ligand superfamily member 4 inhibitor” CHEMBL2108720 ↗1“OX40L blockade” PMID 24224471 ↗ Jan 2014 |
| Modality | Monoclonal antibody | “treatment with an anti-OX40L monoclonal antibody (MAb)” PMID 24224471 ↗ Jan 2014 |
| Route | Intravenous | “administered intravenously in 4 doses over 3 months” PMID 24224471 ↗ Jan 2014 |
| Target | TNFSF4 | “Tumor necrosis factor ligand superfamily member 4 inhibitor” CHEMBL2108720 ↗ |